{"product_id":"biolegend-306002","title":"Biolegend, 306002, Purified anti-human CD123 Antibody, 100μg","description":"\u003cp\u003eCD123 is the 70 kD transmembrane α chain of the IL-3 receptor. Alone, CD123 binds IL-3 with low affinity; when CD123 associates with CD131 (common β chain), it binds IL-3 with high affinity. CD123 does not transduce intracellular signals upon binding IL-3 and requires the β chain for this function. CD123 is expressed by myeloid precursors, macrophages, dendritic cells, mast cells, basophils, megakaryocytes, and some B cells.\u003cbr\u003e\n100μg\u003cbr\u003e\nVerified Reactivity: Human\u003cbr\u003e\nReported Reactivity: Rhesus\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Mouse\u003cbr\u003e\nImmunogen: Human IL-3Rα transfected COS cells.\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography.\u003cbr\u003e\nConcentration: 0.5 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C.\u003cbr\u003e\nApplication: FC - Quality tested CyTOF® - Verified IHC-F, IP, WB - Reported in the literature, not verified in house\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nApplication Notes: Clone 6H6 does not inhibit IL-3 binding to low- or high-affinity IL-3Rs. Additional reported applications (for the relevant formats) include: Western blotting1, immunoprecipitation1, and immunohistochemical staining of acetone-fixed frozen sections2 and also paraformaldehyde fixed paraffin embedded tissue7.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Sun Q, et al. 1996. Blood 87:83. (IP, WB) Herling M, et al. 2003. Blood 101:5007. (IHC) Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Martin-Gayo E, et al. 2010. Blood 115:5366. PubMed Chen SC, et al. 2010. Arch Dermatol Res. 302:113. PubMed Liu Y, et al. 2012. Food Chem Toxicol. 50:1920. PubMed Peduzzi E, et al. 2007. J. Invest. Dermatol. 127:638. (IHC)\u003cbr\u003e\nProduct Citations: Dallari S, et al. 2017. Nat Commun. 8:14830. PubMed Leader AM, et al. 2021. Cancer Cell. 39:1594. PubMed McCarthy EE, et al. 2022. Cell Rep. 39:110815. PubMed Laggner M, et al. 2022. EBioMedicine. 81:104093. PubMed Poon MML, et al. 2023. Nat Immunol. 24:309. PubMed Friebel E, et al. 2020. Cell. 181(7):1626-1642.e20. PubMed Rosa TLSA, et al. 2022. Front Med (Lausanne). 9:899998. PubMed Wagner J et al. 2019. Cell. 177(5):1330-1345 . PubMed Parackova Z, et al. 2020. Sci Rep. 0.759027778. PubMed Kremenovic M, et al. 2020. Cancers (Basel). 12:. PubMed Mann ER, et al. 2020. Sci Immunol. :5. PubMed Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed Vivanco Gonzalez N, et al. 2022. STAR Protoc. 3:101280. PubMed Li Y, et al. 2019. Front Immunol. 0.460416667. PubMed Martin JC, et al. 2020. Cell. 178(6):1493-1508.e20.. PubMed Syrimi E, et al. 2021. iScience. 24:103215. PubMed O'Boyle KC, et al. 2020. Methods Mol Biol. 2111:1. PubMed Chen S, et al. 2010. Arch Dermatol Res. 302:113. PubMed Olin A, et al. 2018. Cell. 174:1277. PubMed Tripathi T, et al. 2019. Immunohorizons. 0.201388889. PubMed Baskar R, et al. 2022. Cell Rep Methods. 2:. PubMed Liu Y, et al. 2012. Food Chem Toxicol. 50:1920. PubMed Eccles JD, et al. 2020. Cell Rep. 30:351. PubMed Thrash EM, et al. 2020. STAR Protoc. 1:100055. PubMed Martin-Gayo E, et al. 2010. Blood. 115:5366. PubMed Henrick BM, et al. 2021. Cell. . PubMed Roussel M, et al. 2021. Cell Reports Medicine. 2(6):100291. PubMed Kato M, et al. 2021. PLoS One. 16:e0252116. PubMed Liu SQ, et al. 2021. Cancer Immunol Res. 9:34. PubMed Evrard M et al. 2018. Immunity. 48(2):364-379 . PubMed NULL, et al. 2022. Cell. 185:916. PubMed Saygin C, et al. 2021. Leukemia. 35:3406. PubMed Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed Chevrier S, et al. 2018. Cell Syst. 0.675. PubMed Lavin Y et al. 2017. Cell. 169(4):750-765 . PubMed\u003cbr\u003e\nRRID: AB_314576 (BioLegend Cat. No. 306002)\u003cbr\u003e\nStructure: Ig superfamily, type I transmembrane glycoprotein, associates with CDw131, 70 kD\u003cbr\u003e\nDistribution: Myeloid precursors, basophils, mast cells, macrophages, dendritic cells, megakaryocytes, subset of lymphocytes\u003cbr\u003e\nFunction: Hematopoietic cell proliferation, differentiation\u003cbr\u003e\nLigand\/Receptor: IL-3\u003cbr\u003e\nCell Type: Basophils, Dendritic cells, Hematopoietic stem and progenitors, Lymphocytes, Macrophages, Mast cells, Megakaryocytes\u003cbr\u003e\nBiology Area: Immunology\u003cbr\u003e\nMolecular Family: CD Molecules, Cytokine\/Chemokine Receptors\u003cbr\u003e\nAntigen References: 1. Miyajima A, et al. 1993. Blood 82:1960.\u003cbr\u003e\nGene ID: 3563\u003cbr\u003e\nUniProt: View information about CD123 on UniProt.org\u003cbr\u003e\nClone: 6H6\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: IL-3Rα, IL-3 Receptor alpha\u003cbr\u003e\nIsotype: Mouse IgG1, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46862481359017,"sku":"306002","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/biolegend-306002","provider":"Iright","version":"1.0","type":"link"}